Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations

Podobne zapisy

• Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI
  od: Okuma, Yusuke, i wsp.
  Wydane: (2017)
• Clinical efficacy of EGFR-TKIs in combination with chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations
  od: Zhang, Minghui, i wsp.
  Wydane: (2016)
• Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
  od: Xue YANG, i wsp.
  Wydane: (2022-05-01)
• P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
  od: Fiala, Ondrej, i wsp.
  Wydane: (2014)
• Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
  od: Miyashita, Yosuke, i wsp.
  Wydane: (2020)